[1]隋文峰,马海英.低分子肝素治疗急性肺栓塞的疗效[J].医学信息,2020,33(16):118-120.[doi:10.3969/j.issn.1006-1959.2020.16.036]
　SUI Wen-feng,MA Hai-ying.Efficacy of Low Molecular Weight Heparin in the Treatment of Acute Pulmonary Embolism[J].Medical Information,2020,33(16):118-120.[doi:10.3969/j.issn.1006-1959.2020.16.036]
点击复制

低分子肝素治疗急性肺栓塞的疗效()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
33卷
期数:
2020年16期
页码:
118-120
栏目:
临床研究
出版日期:
2020-08-15

文章信息/Info

Title:
Efficacy of Low Molecular Weight Heparin in the Treatment of Acute Pulmonary Embolism
文章编号:
1006-1959（2020）16-0118-03
作者:
隋文峰; 马海英
（大连市中心医院呼吸二科，辽宁 大连 116033）
Author(s):
SUI Wen-feng; MA Hai-ying
(Department of Respiratory Medicine,Subject Two,Dalian Central Hospital,Dalian 116033,Liaoning,China)
关键词:
低分子肝素; 急性肺栓塞; 血氧分压; 呼吸状况
Keywords:
Low molecular weight heparin; Acute pulmonary embolism; Blood oxygen partial pressure; Respiratory status
分类号:
R563.5
DOI:
10.3969/j.issn.1006-1959.2020.16.036
文献标志码:
A
摘要:
目的 探讨急性肺栓塞患者采用低分子肝素治疗的效果，为临床治疗该病提供参考。方法 选取2017年1月~2018年12月我院收治的急性肺栓塞患者78例，采用随机数字表法分为对照组和研究组，每组39例。对照组进行普通肝素治疗，研究组行低分子肝素治疗。比较两组临床疗效、二氧化碳分压（PaCO2）、血氧分压（PaO2）、心率、肺动脉压力、MRC呼吸困难评分。结果研究组治疗总有效率为92.31%，高于对照组的79.48%，差异有统计学意义（P＜0.05）；研究组的PaCO2水平为（36.94±3.04）mmHg、PaO2水平为（87.29±3.36）mmHg，高于对照组的（30.37±3.63）mmHg、（76.48±3.37）mmHg，差异有统计学意义（P＜0.05）；研究组心率为（68.55±10.12）次/min，低于对照组的（78.57±10.29）次/min，差异有统计学意义（P＜0.05）；研究组的肺动脉压力为（20.05±6.23）mmHg、MRC呼吸困难评分为（1.22±0.97）分，低于对照组的（26.64±7.99）mmHg、（2.44±0.84）分，差异有统计学意义（P＜0.05）。结论 采用低分子肝素治疗急性肺栓塞可提升临床治疗效果，改善患者二氧化碳分压、血氧分压、心率及肺动脉压力水平，降低MRC呼吸困难评分。
Abstract:
Objective To explore the effect of low-molecular-weight heparin in patients with acute pulmonary embolism, and provide references for clinical treatment of the disease.Methods A total of 78 patients with acute pulmonary embolism admitted to our hospital from January 2017 to December 2018 were selected and divided into control group and study group by random number table, with 39 cases in each group. The control group received unfractionated heparin treatment, and the study group received low molecular weight heparin treatment. The clinical efficacy, partial pressure of carbon dioxide (PaCO2), partial pressure of blood oxygen (PaO2), heart rate, pulmonary artery pressure, and MRC dyspnea score were compared between the two groups.Results The total effective rate of treatment in the study group was 92.31%, which was higher than 79.48% in the control group,the difference was statistically significant (P＜0.05); the PaCO2 level of the study group was (36.94±3.04) mmHg and the PaO2 level was (87.29±3.36) mmHg, higher than the control group (30.37±3.63) mmHg, (76.48±3.37) mmHg, the difference was statistically significant (P＜0.05); the study group’s heart rate was (68.55±10.12) beats/min, lower than the control group (78.57±10.29) times/min, the difference was statistically significant (P＜0.05); the pulmonary artery pressure of the study group was (20.05±6.23) mmHg, and the MRC dyspnea score was (1.22±0.97), which was lower than that of the control group (26.64±7.99) mmHg, (2.44±0.84), the difference was statistically significant (P<0.05).Conclusion The use of low molecular weight heparin in the treatment of acute pulmonary embolism could improve the clinical treatment effect, improve the patients’ carbon dioxide partial pressure, blood oxygen partial pressure, heart rate and pulmonary artery pressure levels, and reduce the MRC dyspnea score.

参考文献/References:

[1]党永康,姜学超,杨柳,等.利伐沙班在急性肺动脉栓塞介入治疗中的应用[J].中华普通外科杂志,2018,33(10):853-856.[2]诸海军,孙杰,陈嵩,等.老年血压正常伴右心功能不全的急性肺栓塞患者的临床分析[J].中华老年医学杂志,2019,38(7):746-749.[3]Jong LAD,Dvortsin E,Janssen KJ,et al.Cost-effectiveness Analysis for Apixaban in the Acute Treatment and Prevention of Venous Thromboembolism in the Netherlands[J].Clinical Therapeutics,2017,39(2):A651.[4]胡梦玮,张思泉.中药联合华法林治疗急性次大面积肺栓塞的临床疗效[J].中华中医药学刊,2019,56(8):2029-2032.[5]韩宁,许雅娟.固肾安胎丸联合低分子肝素干预复发性流产妇女血栓前状态的疗效[J].中成药,2017,35(12):2481-2484.[6]Rajpurkar M,Biss T,Amankwah EK,et al.Pulmonary embolism and in situ pulmonary artery thrombosis in paediatrics:A systematic review[J].Thrombosis and Haemostasis,2017,117(6):1199-1207.[7]白云飞,房体刚,孙瑞.老年全髋关节置换后利伐沙班与低分子肝素预防深静脉血栓形成及失血情况对比[J].中国组织工程研究,2018,22(15):2303-2308.[8]贾淇淇,廖红娟,刘伟伟,等.遗传性异常纤维蛋白原血症右心房反复血栓超声表现1例[J].中华超声影像学杂志,2018,27(11):1005.[9]Enea I,Roncon L,Gulizia MM,et al.ANMCO Position Paper:The use of non-Vitamin K dependent new oral anticoagulant(s)in pulmonary embolism therapy and prevention[J].European Heart Journal Supplements,2017,19(D):293-308.[10]陈剑飞,宋耀明,晋军,等.经皮导管介入术治疗急性肺栓塞的初步探讨[J].中华心血管病杂志,2018,46(12):972-975.[11]李玄庶,张学民,贾哲,等.急性肺栓塞的介入治疗[J].中华普通外科杂志,2017,32(2):129-132.[12]Howard JT,Stockinger ZT,Cap AP,et al.Military use of tranexamic acid in combat trauma:Does it matter[J].Journal of Trauma and Acute Care Surgery,2017,83(4):579-588.

相似文献/References:

[1]钱朝庆,刘 淼,王家平,等.肾病综合征合并肾静脉血栓应用阿加曲班疗效评价[J].医学信息,2018,31(21):135.[doi:10.3969/j.issn.1006-1959.2018.21.038]
　QIAN Chao-qing,LIU Miao,WANG Jia-ping,et al.Clinical Efficacy Evaluation of Argatroban in Nephrotic Syndrome with Renal Vein Thrombosis[J].Medical Information,2018,31(16):135.[doi:10.3969/j.issn.1006-1959.2018.21.038]
[2]陈志萍.阿托伐他汀联合低分子肝素治疗短暂性脑缺血临床疗效[J].医学信息,2019,32(09):153.[doi:10.3969/j.issn.1006-1959.2019.09.051]
　CHEN Zhi-ping.Clinical Efficacy of Atorvastatin Combined with Low Molecular Weight Heparin in the Treatment of Transient Cerebral Ischemia[J].Medical Information,2019,32(16):153.[doi:10.3969/j.issn.1006-1959.2019.09.051]
[3]王晓芳.低分子肝素治疗COPD合并Ⅱ型呼吸衰竭的临床疗效[J].医学信息,2019,32(19):155.[doi:10.3969/j.issn.1006-1959.2019.19.051]
　WANG Xiao-fang.Clinical Efficacy of Low Molecular Weight Heparin in the Treatment of COPD with Type II Respiratory Failure[J].Medical Information,2019,32(16):155.[doi:10.3969/j.issn.1006-1959.2019.19.051]
[4]沙梦晗,陈素华,亢庆玲,等.低分子肝素治疗胎儿生长受限的临床疗效分析[J].医学信息,2019,32(14):61.[doi:10.3969/j.issn.1006-1959.2019.14.020]
　SHA Meng-han,CHEN Su-hua,Kang Qing-ling,et al.Clinical Analysis of Low Molecular Weight Heparin in the Treatment of Fetal Growth Restriction[J].Medical Information,2019,32(16):61.[doi:10.3969/j.issn.1006-1959.2019.14.020]
[5]刘 伟,徐 平,黄文彬,等.sPESI与PESI对于非高危急性肺栓塞患者 危险分层结果的比较[J].医学信息,2019,32(16):70.[doi:10.3969/j.issn.1006-1959.2019.16.021]
　LIU Wei,XU Ping,HUANG Wen-bin,et al.Comparison of sPESI and PESI for Risk Stratification in Patients with Non-high-risk Acute Pulmonary Embolism[J].Medical Information,2019,32(16):70.[doi:10.3969/j.issn.1006-1959.2019.16.021]
[6]龚嘉玮,朱旭日,徐 锋,等.化瘀定痛液联合低分子肝素治疗老年粗隆间骨折围手术期肿痛的效果[J].医学信息,2020,33(03):148.[doi:10.3969/j.issn.1006-1959.2020.03.048]
　GONG Jia-wei,ZHU Xu-ri,XU Feng,et al.Effect of Huayudingtong Liquid Combined with Low-molecular-weight Heparin on Perioperative Swelling and Pain in Elderly Intertrochanteric Fractures[J].Medical Information,2020,33(16):148.[doi:10.3969/j.issn.1006-1959.2020.03.048]
[7]苏振华.血清BNP、TnⅠ及Hcy水平与急性肺栓塞患者病情严重程度及预后的关系[J].医学信息,2020,33(05):175.[doi:10.3969/j.issn.1006-1959.2020.05.060]
　SU Zhen-hua.The Correlation Between of Serum BNP,TnⅠ and Hcy Levels in the Severity and Prognosis of Patients with Acute Pulmonary Embolism[J].Medical Information,2020,33(16):175.[doi:10.3969/j.issn.1006-1959.2020.05.060]
[8]刘廷胜.低分子肝素结合瑞舒伐他汀与醋酸泼尼松对肾病综合征患者肾功能及炎症因子的影响[J].医学信息,2020,33(08):158.[doi:10.3969/j.issn.1006-1959.2020.08.052]
　LIU Ting-sheng.Effect of Low Molecular Weight Heparin Combined with Rosuvastatin and Prednisone Acetate in the Treatment of Patients with Nephrotic Syndrome[J].Medical Information,2020,33(16):158.[doi:10.3969/j.issn.1006-1959.2020.08.052]
[9]周浩东,哈敏文.低分子肝素对晚期非小细胞肺癌化疗疗效及预后的影响[J].医学信息,2020,33(10):161.[doi:10.3969/j.issn.1006-1959.2020.10.049]
　ZHOU Hao-dong,HA Min-wen.Effects of Low Molecular Weight Heparin on the Efficacy and Prognosis of Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer[J].Medical Information,2020,33(16):161.[doi:10.3969/j.issn.1006-1959.2020.10.049]
[10]林 瑛,刘兰兰,江美娇.低分子肝素联合气压治疗预防剖宫产术后下肢深静脉血栓的临床效果[J].医学信息,2023,36(22):132.[doi:10.3969/j.issn.1006-1959.2023.22.030]
　LIN Ying,LIU Lan-lan,JIANG Mei-jiao.Clinical Effect of Low Molecular Weight Heparin Combined with Pneumatic Compression in the Prevention of Deep Venous Thrombosis After Cesarean Section[J].Medical Information,2023,36(16):132.[doi:10.3969/j.issn.1006-1959.2023.22.030]

更新日期/Last Update: 1900-01-01